PharmaTimes -
January/February 2021

Despite entering another national lockdown, we begin this year with a great deal more hope for a return to ‘normality’ than with which we finished 2020. Following an unprecedented global, collaborative push for a COVID-19 vaccine, we now have three approved for use in the UK and the country’s largest vaccination programme in its history is rapidly underway. However, the devastating daily death tolls (which were still reaching new heights as PharmaTimes was going to press) and emergence of new variations of the virus serve as a stark reminder that the fight is far from over, and that the true impact of the pandemic is yet to be revealed.

In this issue, Oli Hudson outlines (p16) what we know so far about the impact of the pandemic on prescribing patterns. Pharma companies need to be sensitive to any changes to care pathways as a result of COVID-19 that might be leaving patients with suboptimal treatment plans, he notes. Over on page 20, Dr Andrew Rut considers what pharma companies can do to help drive COVID-19 vaccination, including creating a complete picture of safety as soon as possible, which will be no mean feat given the expected deluge of pharma call centre vaccination inquiries and reports.

Our cover feature (p24) looks at the new era of medical communications which is forging ever closer links between pharma, patients and healthcare, and we talk to two communicators in the field about their roles and experiences (p27). Speaking of new eras, Paul McGrade highlights (p18) what the pharma industry should be focusing on now given that a trade deal has been agreed between the UK and the EU.

I hope you enjoy the issue!

Up next month: Pharma and the NHS – where is the relationship going? We explore partnerships, joint working, the emergence of digital and an international pandemic – all factors that have rebooted inter-sector relations between the two powerhouses of healthcare. What will define the NHS-pharma bond over the next decade? You can help shape this article - for more information, please email Anna Yeardley anna.yeardley@pharmatimes.com

Digital edition sponsored by

Advertisement

January 2021 - magazine highlights

Thumbnail image for The innovation opportunity

The innovation opportunity

Dr Paul Cornes looks at the success and promise of biosimilar medicines as driver and enablers of innovation

Thumbnail image for COVID-19: a tough pill to swallow for drug prescribing?

COVID-19: a tough pill to swallow for drug prescribing?

While recent vaccine developments provide a glimpse of a post-COVID future, the ongoing impact of the pandemic on prescribing patterns is still being closely scrutinised. Oli Hudson looks at what the data tells us so far, and where things might go from here

Thumbnail image for News travels fast

News travels fast

Communication between pharma, patients and wider healthcare has helped to create a solid foundation upon which the general public understands disease and, crucially, trusts emerging therapies. Now that vaccines promise a ‘way out’ of the COVID-19 impasse, pharma’s direction has never (ever) been more important

Thumbnail image for Cold chain in 2021

Cold chain in 2021

Dave Williams' predictions for COVID-19's continued influence on the industry

Thumbnail image for Shaping the future

Shaping the future

EB McLindon considers whether 2020 will accelerate transformation in approach for longer term resilience in clinical research

Thumbnail image for Patient Files: XLH

Patient Files: XLH

PharmaTimes talks to Emily McKechnie about the rare genetic disorder XLH and the Shine a Light on XLH campaign

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download